bunch of white oval medication tablets and white medication capsules

Inogen (NasdaqGS:INGN) Q3 2020 Earnings Prep


Inogen, Inc. (NasdaqGS:INGN) is scheduled to report Q3 earnings results after markets close for trading on November 4, 2020.

The company is expected to report earnings of -$0.09/share on revenue of $76.064 million. The consensus earnings per share (EPS) of -$0.09/share is based on a poll of 4 analysts and represents a decline in eps of −128.8% over the same quarter last year, when the company reported earnings of $0.31/share.

The revenue forecast of $76.064 million based on a poll of 6 analysts implies a year-over-year (YoY) decline in revenue of −17.1%. Last year the company reported $91.761 million in revenue for the quarter.

Expected to report EPS of -$0.09/share for Q3, 2020
Metric Expected Prior Year YoY Change
Revenue $76.06 $91.76 −17.1%
EPS -$0.09 $0.31 −128.8%

Earnings Call Trends

Historically, management has exceeded analyst expectations 5 out of the last 8 tracked quarters, and missed expectations 3 quarters.

What are your expectations from Inogen, Inc. for earnings this quarter? Let us know in the comments!

Analyst Expected vs. Reported EPS
Quarter Expected Reported Surprise Result
Q2, 2020 -$0.06 $0.12 296.9% Beat
Q1, 2020 -$0.11 -$0.07 36.7% Beat
Q4, 2019 $0.09 -$0.06 -165.1% Missed
Q3, 2019 $0.22 $0.31 38.8% Beat
Q2, 2019 $0.49 $0.45 -8.2% Missed
Q1, 2019 $0.33 $0.24 -27.0% Missed
Q4, 2018 $0.25 $0.44 76.7% Beat
Q3, 2018 $0.53 $0.73 38.3% Beat

In the following table, we summarize the company’s stock price movements after earnings releases. The “Price Day Prior” column shows the closing stock price on the day before the earnings report, and the “Price Next Day” column shows the stock price at the end of the trading day after the earnings report. After the last earnings report for the period ending June 30, 2020, the stock price reacted by increasing 16.4%.

Stock Price Performance After Earnings
Report Date Price Day Prior Price Next Day Change % Result
August 4, 2020 $29.82 $34.72 16.4% Increase
May 5, 2020 $50.26 $39.51 −21.4% Decline
February 25, 2020 $43.44 $47.88 10.2% Increase
November 5, 2019 $57.70 $67.69 17.3% Increase

The other question to consider is one of earnings manipulation. There is a lot of pressure on management each quarter to deliver on earnings expectations. The Beneish M-Score is a statistical model that provides some insight into whether the company might be manipulating earnings. With a Beneish M-Score of −2.36, the model suggests that the company is not likely to be an earnings manipulator. A value of −2.36 implies a 0.9% chance of earnings manipulation.

Fundamentals And Technical Analysis

Inogen, Inc. is currently trading at $28.33/share, down −1.7% for the day. The company is trading at approximately 36.9% of its 52-week high of $76.89/share. The company’s stock price is down −18.4% since the last earnings report and up 2.2% over the previous week. The company’s 14 Day Relative Price Index (RSI) of 48.82 suggests the company is trading in technically neutral territory. The RSI is considered overbought when above 70 and oversold when below 30.

NasdaqGS:INGN Stock Price Chart
Source: Finbox

The current share price implies a price-to-earnings (P/E) multiple of 95.80 and a forward P/E multiple of −188.08.

Inogen, Inc.’s current share price also implies a price-to-book (P/B) multiple of 1.77. The following table summarizes some other key fundamental ratios:

Data as of October 28, 2020
Metric Value
Last Reported Fiscal Period Key FY2020.Q2
Period End Date June 30, 2020
Stock Price (Current) $28.33
P/E Ratio 95.8x
P/E Ratio (Fwd) −188.1x
PEG Ratio −1.2
Total Debt / Total Capital 1.6%
Levered Free Cash Flow $29.698 million
EV / EBITDA 26.3x


Inogen, Inc. is a small-cap stock with a market capitalization of $636.2 million and a total enterprise value of $428 million. The company operates in the Healthcare sector and the Healthcare Equipment & Supplies industry.

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.

Expertise: financial technology, analyzing market trends. Brian is a founder at finbox.io, where he’s focused on building tools that make it faster and easier for investors to research stock fundamentals. Brian’s background is in physics & computer science and previously worked as a software engineer at GE Healthcare. He enjoys applying his expertise in technology to help find market trends that impact investors. Brian can be reached at brian@finbox.io or at +1 (516) 778-6257.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.